Biotalys, a pioneering agtech company specializing in developing biocontrols using its innovative AGROBODY™ technology platform, has announced its consolidated financial results for 2022. Despite the global challenges of the past year, Biotalys achieved significant milestones and progress in its key focus areas. The company has established strategic partnerships with industry leaders, such as Olon, Kwizda Agro, and Novozymes, to prepare for the market calibration of its first bio-fungicide product, Evoca.
Biotalys made a breakthrough in protein expression for Evoca’s bioactive ingredient, substantially lowering production costs for both Evoca and future product candidates. The company also earned a new mode of action class from the Fungicide Resistance Action Committee (FRAC) for Evoca’s active ingredient, further cementing the innovation and scientific value of the product.
Regarding regulatory updates, Biotalys has submitted its dossier for Evoca to relevant authorities in both the U.S. and E.U. The U.S. Environmental Protection Agency (EPA) is currently reviewing it. The company expects to obtain the registration for Evoca in Q3 2023, allowing the product’s use in selected fruit and vegetable crops. Biotalys plans to launch the commercial version of Evoca in Europe in 2026, following its expected first registration in the E.U. in 2025.
Biotalys’ pipeline of product candidates, including novel bio fungicides, bio bactericides, and bio-insecticides, has also progressed according to plan. The next generation of Evoca, with optimized manufacturing and formulation, is expected to enter the U.S. and E.U. markets by 2026, subject to regulatory approval. In addition, bioFun-6, another product candidate, moved into in-depth in vitro characterization in 2022 to obtain a novel mode of action that differentiates it from Evoca. The company expects to move BioFun-6 into the development stage by the end of 2023, with a target launch date of 2028.
Biotalys made necessary appointments throughout the year to support its continued growth and success, including Dr. Carlo Boutton as Chief Scientific Officer. In addition, Biotalys’ CEO Patrice Sellès emphasized that the company’s focus and strategy align with the global need to safely and sustainably feed the world while addressing chemical pesticide reduction targets. The complete financial report, including the annual report, will be published on Biotalys’ website on March 24, 2023.
Read the biotalys financial results here.
Photo by Karoline Stk on Unsplash
You must log in to post a comment.